Aprea Therapeutics, Inc. (APRE) Stock Price & Analysis
Aprea Therapeutics, Inc. (APRE) rose 0.57% to USD 0.74 as of June 10, 2026 at 03:07 UTC, according to Nexqual real-time market data.
APRE last closed at USD 0.73; the session ranged USD 0.7–0.77 on volume of 91,177 shares. Market capitalization is $9.14M, with a 52-week range of USD 0.55–2.22 (NCM). Source: Nexqual, June 10, 2026 at 03:07 UTC.
Key Statistics (as of June 10, 2026 at 03:07 UTC)
| Price | USD 0.74 |
|---|---|
| Change | ▲ 0.57% (up) |
| Previous Close | USD 0.73 |
| Open | USD 0.77 |
| Day Range | USD 0.7 – 0.77 |
| 52-Week Range | USD 0.55 – 2.22 |
| Volume | 91,177 shares |
| Market Cap | $9.14M |
| Exchange | NCM |
Technical Analysis (APRE)
Nexqual's technical model rates APRE "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.9 (neutral) |
| vs SMA50 | Below (USD 0.85) |
| MACD | -0.03 (negative) |
Analyst Ratings (APRE)
Wall Street analysts rate APRE "None" based on 4 analysts, with a mean price target of USD 4.3 (range USD 1.2–6), per Nexqual as of June 10, 2026 at 03:07 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 4.3 |
| High Target | USD 6 |
| Low Target | USD 1.2 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (APRE)
| EPS Estimate | USD -0.22 |
|---|---|
| Revenue Estimate | $126,500 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.22 vs est -0.23 ▲ beat |
| 2025-12-31 | USD -0.32 vs est -0.36 ▲ beat |
| 2025-09-30 | USD -0.47 vs est -0.1 ▼ miss |
| 2025-06-30 | USD -0.53 vs est -0.71 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financials & Fundamentals (APRE)
| Total Revenue | $123,296 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -10202.01% |
| Profit Margin | +0.00% |
| ROE | -40.40% |
| Current Ratio | 8.92 |
| Total Cash | $46.47M |
| Total Debt | $0 |
| Free Cash Flow | $-5.63M |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financial Health Score (APRE)
Nexqual rates Aprea Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:07 UTC.
| Growth | Critical — Revenue -81% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $46M cash, no debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -40%, ROA -23.2% |
Ownership (APRE)
| Insider Ownership | +11.56% |
|---|---|
| Institutional Ownership | +18.13% |
| Shares Outstanding | 12.38M |
| Float | 7.26M |
| Short % of Float | +1.02% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Leadership (APRE)
Aprea Therapeutics, Inc. is led by Oren Gilad (age 57), Co-Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 03:07 UTC.
| Co-Founder, CEO, President & Director | Oren Gilad (age 57) |
|---|---|
| Senior VP, CFO, Principal Accounting Officer & Secretary | John P. Hamill (age 61) |
| Senior VP & Chief Scientific Officer | Lars B. Abrahmsen (age 68) |
| Senior Vice President of Corporate Development & Strategy | Brian Wiley (age 57) |
Major Backers & Investors (APRE)
Notable institutional backers of Aprea Therapeutics, Inc. include AIGH Capital Management LLC, Vestal Point Capital, LP, Sphera Funds Management Ltd., according to Nexqual as of June 10, 2026 at 03:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 8.2% |
| Vestal Point Capital, LP | 2.83% |
| Sphera Funds Management Ltd. | 2.18% |
| Nantahala Capital Management, LLC | 1.66% |
| Fidelity | 0.95% |
| Scientech Research LLC | 0.49% |
| BNP Paribas Financial Markets | 0.32% |
| Renaissance Technologies | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.96% |
| Vanguard Group | 0.47% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
From Aprea Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
- If it becomes necessary for us to use patented or proprietary technology of third parties to develop or commercialize our product candidates, we may need to seek a license from such third parties.
- Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.
- Our approach is to inhibit these make up genes, thereby specifically killing cancer cells with defined mutations.
Partnerships
- APR-1051 Exhibits Strong Tumor Control in CCNE1-Overexpressing CDX Model In addition, pre-clinical results from an ongoing translational research collaboration with renowned oncology leader MD Anderson Cancer Center support the potential of APR-1051 both as a single agent and in rational immunotherapy combinations in HPV+ head and neck squamous cell carcinoma (HNSCC).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GRTX | Galera Therapeutics, Inc. | USD 0.09 | ▼ 2.11% |
| ASMB | Assembly Biosciences, Inc. | USD 22.72 | ▼ 0.79% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 3 | ▲ 0.67% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.36 | ▲ 2.27% |
| BYSI | BeyondSpring, Inc. | USD 1.72 | ▲ 0.58% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:07 UTC. This page is informational and not investment advice.